A regularly heard talking point is that follow-on drugs, such as biosimilars and generics, will bring down prices through competition. But, they don’t invariably do so. PBMs may favor more expensive branded products over similar or even bioequivalent versions that are cheaper.
U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of Biosimilars
